WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: NOVEMBER ISSUE PUBLISHED
  • NOVEMBER 2024 Issue has been successfully launched on NOVEMBER 2024.

Abstract

DEVELOPMENT AND VALIDATION OF STABILITY INDICATING METHOD FOR SIMULTANEOUS ESTIMATION OF CEFTAZIDIME AND TAZOBACTAM INJECTION USING RP-UPLC METHOD

Panchal Vipul J*, Desai Hemant T, Patel Nirav B and Panchal Kalpesh B

ABSTRACT

This research manuscript describes simple, sensitive, accurate, precise and repeatable RP- UPLC method for the simultaneous determination of Ceftazidime (CTZ) and Tazobactam (TAZ) Injection in combine dosage form. The sample was analyzed by reverse phase C18 column (Acquity UPLC BEH 100 × 2.1 mm ID, 1.7 μm) with mobile phase. In mobile phase, Solution A containing Potassium Dihydrogen Phosphate buffer (pH adjusted to 6.5±0.2 with Orthophosphoric acid), Citric acid buffer (pH adjusted to 5.0±0.2 with NaoH solution) and Acetonitrile and Solution B containing Tetradecyl ammonium bromide, Tetraheptyl ammonium bromide and Acetonitrile in the flow rate of 0.3 ml/min. Quantification was achieved 230 nm with PDA detector. The retention time for Ceftazidime and Tazobactam was found to be 1.02 and 1.69 minute respectively. The linearity for Ceftazidime and Tazobactam was obtained in the concentration range of 40-280 μg/ml and 5-35 μg/ml respectively. Ceftazidime and Tazobactam API and market formulation were subjected to acid and alkali hydrolysis, oxidation, thermal and photolytic forced degradation. The peak purity of drug substance and drug product peak also confirmed the specificity of the methods with respect to the degradation products. In the forced degradation study Ceftazidime and Tazobactam showed maximum degradation in base hydrolysis stress study followed by less degradation in thermal degradation. The developed method was simple, specific, sensitive, rapid, and economic and can be used for estimation of Ceftazidime and Tazobactam in bulk and their combined dosage form for routine analysis and stability studies.

Keywords: Ceftazidime, Tazobactam, Method validation, RP-UPLC, Forced degradation.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More